Articles

  1. Development and Manufacturing Equipment List 1/13/2014

    Norwich is a leader in solid dose pharmaceutical production. We offer expertise, comprehensive manufacturing and packaging support from clinical trial through scale-up and to commercial launch.

  2. The Environmental Impact of Clinical Trials 8/8/2013

    For many years it has been almost universally accepted that there are various sources that may impact or cause disease among which biological, social, and environmental differences have all been investigated. Many clinical trials have been conducted to assess the impact of the environment on outcomes e.g., the effect of the environment on the outcome of studies assessing the efficacy of drugs for patients with dry-eye syndrome, the impact of diet on obesity and cardiovascular disease, and the impact of the environment on autoimmune diseases have all been studied, as have many other interactions.

  3. Brochure: Norwich Clinical Services 2/1/2013

    Norwich Clinical Services is a contract research organization that provides Bioanalytical Services, Pharmacovigilance and Clinical Research Programs to the pharmaceutical and biotech industries.

  4. Outsourcing In The Pharma Industry – Experience, Expertise And Enthusiasm 6/13/2012

    2012 will be regarded by many commentators as one of the most challenging years in the pharmaceutical industry’s history, due in no small part to numerous products facing patent expirations and increased global competition.

  5. Why Choosing The Right Digital Collaboration Program Is Critical To Future Success 5/30/2012

    Increasing drug development costs, longer trial durations and insufficient rates of success are prompting the search for innovative solutions for clinical trials. As sponsors seek new ways to mitigate risks and maximize opportunities in clinical development efficiencies, many are turning to a digital collaboration platform. By Within3

  6. The Soft Science Of Choosing A CRO 5/29/2012

    Small CROs have had a harder time competing in recent years against the worldwide giants of the field — Quintiles, Covance, PPD, Charles River, ICON, to name a few — in large part because the scary financial environment has prompted pharma and biotech executives to play the safer hand of choosing a large provider to handle their clinical services needs, even when a smaller vendor offers the same services at a competitive price. By Jacquie Mardell, Anhvita BioPharma Consulting

  7. What Does Vertex Look For When Selecting A CRO? 5/24/2012

    Peter A. DiBiaso is the head of clinical business operations for Vertex Pharmaceuticals and responsible for the leadership of clinical business operations in support of Vertex’s global development portfolio. By Rob Wright, Chief Editor, Life Science Leader magazine

  8. Optimizing Clinical Trial Enrollment: Same Day Turnaround Of Blood Chemistry For Eligibility 5/22/2012

    Potential clinical trial participants and sponsors typically wait 2-3 days for lab results to determine eligibility. For the would-be participant every day that elapses could contribute to the loss of interest and increase the risk of losing a potential study subject for many reasons. By Paul S. Savuto, MS, MBA Blinded Diagnostics

  9. Outsourcing Insights: Focusing On Innovation 4/12/2012

    In 2011, innovation was a major topic among the various players in the drug development industry. By Kate Hammeke, research manager, Nice Insight

  10. Weathering The Sunshine Act 4/4/2012
    The Sunshine Act is a provision in the Patient Protection and Affordable Care Act, signed into law in March 2010. The Sunshine Act requires drug companies, medical device manufacturers and group purchasing organizations (GPOs) to report to the Department of Health and Human Services (HHS) certain payments or other transfers of value they make to physicians and teaching hospitals.